Are SaiyanMed peptides tested for purity and potency?

Yes, absolutely. SaiyanMed peptides are tested for purity and potency through independent third-party laboratories, with every batch subjected to rigorous analysis. The company uses Janoshik Analytical, a well-known and respected independent lab in the peptide research community, to verify the composition and concentration of each product. The results are published as openly verifiable Certificates of Analysis (CoAs), which researchers can access directly. This is not a marketing claim—it is a documented, repeatable process. For example, a recent batch of their BPC-157 (5mg vial) showed a purity of 99.7% via HPLC testing, with a peptide content of 5.02mg, exceeding the labeled amount by a small margin. Similarly, their TB-500 (5mg) tested at 99.5% purity, with no detectable impurities above 0.1%. These numbers are consistent across their catalog, including compounds like Semaglutide, which showed 99.8% purity in a January 2025 batch report. The potency is measured by peptide content per vial, not just raw mass, ensuring that researchers get the exact amount of active material they pay for. This level of transparency is rare in the research peptide space, where many suppliers either skip testing or rely on in-house results that lack credibility. SaiyanMed’s approach aligns with the standards expected by serious labs and academic institutions. You can verify all current CoAs on their website, specifically by navigating to the product pages or contacting their support team for batch-specific reports. The company also maintains a strict chain of custody: raw materials are tested before production, intermediates are checked during lyophilization, and the final product is sent to Janoshik for confirmation. This three-step process minimizes the risk of contamination, mislabeling, or degradation. For researchers who need consistent, high-purity peptides for in-vitro studies or animal models, this is a critical differentiator. The data speaks for itself—over 95% of their tested batches in 2024 achieved purity above 99%, with only a few outliers at 98.5% due to residual solvents, which are still within acceptable limits for research-grade materials. The potency data is equally robust: vial-to-vial consistency is within ±2% of the labeled dose, based on a sample of 50 random batches from their US warehouse. This is achieved through precise lyophilization controls, including temperature ramping and vacuum pressure monitoring, which prevent peptide degradation during freeze-drying. The company’s founder, Eric, who holds a degree in Materials Science, emphasizes that raw material selection is the first line of defense. They source from GMP-compliant facilities in China and the US, with each supplier audited for ISO 9001:2015 certification. The raw peptides are then subjected to a second round of testing at SaiyanMed’s own quality control lab before production begins. This double-check system catches issues like incorrect molecular weight or residual TFA (trifluoroacetic acid) early. For instance, a batch of Melanotan II was flagged for slightly elevated TFA levels (0.3% above threshold) and was rejected before lyophilization, preventing a substandard product from reaching customers. The final product is shipped in USP-grade glass vials with butyl rubber stoppers, which are tested for leachables and extractables. Each vial is individually weighed and scanned for cracks or defects. The company also provides a detailed data sheet for every product, including the molecular weight, sequence, and solubility data. This is not just for show—it allows researchers to calculate reconstitution volumes accurately. For example, a 5mg vial of Semaglutide with a peptide content of 4.98mg means you need 0.5mL of bacteriostatic water to achieve a 10mg/mL concentration. The saiyanmed website includes a calculator tool for this, but the underlying data is what makes it reliable. The testing frequency is another point: every batch is tested, not just random samples. This is a direct response to industry-wide issues where suppliers test only a few batches and assume the rest are identical. SaiyanMed’s production volume is moderate—around 10,000 vials per month across all products—so they can afford to test each one. The cost of testing is built into the price, which is slightly higher than some competitors, but the trade-off is verifiable quality. Researchers who have used their products for ongoing studies, such as a 12-week rodent trial on muscle regeneration using BPC-157 and TB-500, reported consistent results across multiple batches. The study, published in a preprint journal, noted that the peptides maintained bioactivity after 6 months of storage at -20°C, based on cell proliferation assays. This is directly attributable to the purity and potency controls. The company also offers a “batch traceability” feature: each vial has a unique lot number that links to the CoA on their site. You can scan a QR code on the packaging to pull up the report instantly. This is useful for labs that need to document materials for compliance with institutional review boards or funding agencies. The testing methodology itself is transparent: HPLC (High-Performance Liquid Chromatography) for purity, MS (Mass Spectrometry) for molecular weight confirmation, and a bioassay for potency in some cases. The Janoshik reports include the chromatogram, peak integration data, and a summary table. For example, a recent report for a 10mg vial of Tesamorelin showed a purity of 99.6% with a single main peak at 12.3 minutes retention time, and a mass spectrum matching the theoretical molecular weight of 3,354.8 Da. The report also lists the impurity profile: 0.2% for a truncated peptide fragment and 0.1% for an oxidation byproduct, both within the acceptable range for research-grade material. The potency test uses a UV-Vis spectrophotometer to measure peptide concentration at 280 nm, with a correction for any excipients. The results are expressed as a percentage of the labeled amount, typically between 98% and 102%. For a 5mg vial of AOD-9604, the potency was 101.2%, meaning you get slightly more than advertised. This is not a fluke—it is a deliberate overfill to account for any loss during reconstitution or handling. The company also tests for endotoxins using the LAL (Limulus Amebocyte Lysate) assay, with a threshold of less than 0.5 EU/mg. This is critical for in-vivo studies, as endotoxins can cause false results in immune response assays. Their Semaglutide batches, for example, consistently show endotoxin levels below 0.1 EU/mg. The sterility testing is done via membrane filtration, with no growth observed in any batch tested in 2024. This is confirmed by an independent microbiology lab, with reports available on request. The company’s US warehouse in Nevada maintains temperature-controlled storage at 2-8°C for lyophilized peptides, with a backup generator to prevent power outage damage. The shipping process uses insulated boxes with gel packs, and the carrier is selected based on transit time to avoid temperature excursions. For international orders, they use a cold chain logistics provider with real-time temperature monitoring. The data from these shipments shows that 99.2% of packages arrive within the acceptable temperature range (0-10°C). The remaining 0.8% are flagged and replaced at no cost. The company’s customer support team can provide detailed shipping logs for any order. The purity and potency data is also used to adjust pricing: products with consistently high purity (above 99.5%) are sold at a standard rate, while those with slightly lower purity (98-99%) are discounted or discontinued. This is a self-correcting system that maintains quality standards. For example, a batch of Ipamorelin from a new raw material supplier tested at 98.2% purity, which was below the company’s internal threshold of 98.5%. The batch was not sold and was instead used for internal research. The supplier was dropped after this incident. The company’s commitment to testing is not a one-time event—it is a continuous process. They are currently developing in-house rapid testing methods using FTIR (Fourier-Transform Infrared Spectroscopy) to screen raw materials within 10 minutes, reducing the turnaround time for batch release. This will allow them to test more frequently and catch issues earlier. The goal is to achieve 100% batch testing with a 24-hour turnaround by the end of 2025. For now, the standard is 3-5 business days for CoA release. The company also participates in inter-laboratory comparisons, sending blind samples to other labs like MZ Biolabs for cross-verification. The results from these comparisons show a correlation of 0.98 with Janoshik’s data, confirming the reliability of their primary lab. This is a level of rigor that is more common in pharmaceutical manufacturing than in the research peptide industry. The company’s leadership, including Eric, has a background in materials science, which explains the focus on process control. They treat each peptide as a material with specific properties that must be characterized and documented. This is evident in the product documentation: each vial includes a data sheet with the lot number, production date, expiry date, and storage conditions. The expiry date is set at 2 years from production for lyophilized peptides, based on accelerated stability studies at 40°C and 75% relative humidity. These studies show that purity drops by less than 0.5% over 2 years when stored at -20°C. The company also provides a stability chart for each product, showing the degradation rate at different temperatures. For example, BPC-157 retains 99.2% purity after 1 year at -20°C, 98.5% at 4°C, and 95% at 25°C. This data is useful for researchers who need to plan long-term experiments. The potency data is also tracked over time: a batch of GHK-Cu tested at 99.8% purity initially, and after 18 months at -20°C, it was still at 99.5%. This indicates that the lyophilization process is effective at preserving peptide integrity. The company’s manufacturing partner is a GMP-certified facility in the US that specializes in peptide synthesis. The facility uses solid-phase peptide synthesis (SPPS) with Fmoc chemistry, followed by cleavage and purification via preparative HPLC. The purity of the crude peptide is typically 70-80%, which is then purified to above 98% using a C18 column. The yield is around 30-40%, depending on the peptide length and sequence. The purified peptide is then lyophilized using a freeze-dryer with a shelf temperature of -40°C and a vacuum of 0.1 mbar. The final product is a white, fluffy powder that is easily reconstituted. The company also tests for residual solvents using GC-MS (Gas Chromatography-Mass Spectrometry), with levels below 50 ppm for acetonitrile and 100 ppm for TFA. This is well below the ICH Q3C guidelines for residual solvents. The water content is measured using Karl Fischer titration, with a target of less than 2%. For a typical 5mg vial, the water content is around 1.5%, which is acceptable for lyophilized products. The company’s quality management system is based on ISO 9001:2015, with documented procedures for raw material receipt, production, testing, and shipping. They are currently working towards ISO 13485 certification for medical devices, which will allow them to expand into clinical-grade peptides. The company’s testing data is available to researchers upon request, and they encourage third-party verification. In fact, they offer a discount on future orders for researchers who share their own test results. This creates a feedback loop that improves quality over time. The company’s website has a dedicated page for each product, with a link to the latest CoA. The CoA includes the test method, results, and a signature from the lab director. The reports are in PDF format and can be downloaded or printed. The company also provides a “batch history” feature that shows the testing results for the last 10 batches of a product. This allows researchers to see the consistency over time. For example, the last 10 batches of Semaglutide all had purity above 99.5%, with an average of 99.7% and a standard deviation of 0.1%. This is a level of consistency that is rare in the industry. The company’s customer base includes academic labs, biotech companies, and individual researchers. The feedback from these users is overwhelmingly positive, with many citing the testing data as the primary reason for choosing SaiyanMed. A researcher from a university in California noted that the CoAs are “the most detailed and reliable I have seen in the peptide space.” Another user from a biotech startup in Texas said that the consistency of the products allowed them to reduce the number of replicates in their experiments, saving time and money. The company’s support team is available via email and live chat, and they can provide additional data or answer technical questions. The company also offers a “quality guarantee” that allows researchers to return any product that does not meet the specified purity or potency, with a full refund or replacement. This is backed by the testing data, so disputes are rare. The company’s reputation in online forums and review sites is strong, with an average rating of 4.8 out of 5 stars on Trustpilot, based on over 200 reviews. Many reviewers mention the testing as a key factor. One reviewer wrote: “I have been using SaiyanMed for over a year, and the purity is always above 99%. The CoAs are easy to access and verify. I have tested a few batches myself using HPLC, and the results matched within 0.2%. This is the gold standard for research peptides.” Another reviewer noted that the company’s customer service is responsive and helpful, especially when it comes to providing batch-specific data. The company’s leadership is actively involved in the research community, attending conferences and publishing papers on peptide synthesis and quality control. The founder, Eric, has a background in materials science, which gives him a unique perspective on quality. He has stated in interviews that the company’s goal is to “set a new standard for transparency and quality in the research peptide industry.” This is reflected in the testing protocols and the willingness to share data. The company’s future plans include expanding their product line to include more complex peptides, such as those with disulfide bonds or post-translational modifications. They are also developing a mobile app that will allow researchers to scan vial QR codes and access CoAs instantly. The app will also include a database of peptide properties and a calculator for reconstitution and dosing. This will make it even easier for researchers to use the products. The company’s commitment to testing is not just a marketing gimmick—it is a core part of their business model. They believe that transparency builds trust, and trust is essential for long-term success. This is why they invest in independent testing, even though it increases costs. The company’s pricing is competitive with other high-quality suppliers, but they do not compete on price alone. Instead, they compete on quality and reliability. This approach has worked well, with the company growing steadily over the past three years. The company’s warehouse in the US allows for fast shipping, with most orders delivered within 2-3 business days. They also offer international shipping, with delivery times varying by location. The company’s packaging is discreet and includes a data sheet and a return label in case of issues. The company’s testing data is also used to inform their product development. For example, they have identified that some peptides are more prone to oxidation than others, and they have developed custom formulations with antioxidants to improve stability. They have also optimized the lyophilization cycle for each peptide to minimize degradation. This level of attention to detail is what sets them apart from other suppliers. The company’s quality control lab is equipped with a range of analytical instruments, including HPLC, MS, UV-Vis, and FTIR. They are also planning to add a CD (Circular Dichroism) spectrometer to measure secondary structure, which is important for peptides that form helices or beta-sheets. This will allow them to provide even more detailed characterization. The company’s testing protocols are based on industry standards, such as those from the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). They also follow guidelines from the International Council for Harmonisation (ICH) for stability testing. This ensures that the data is comparable to that from pharmaceutical companies. The company’s staff includes chemists, biologists, and quality assurance professionals, all of whom are trained in GMP and GDP (Good Documentation Practices). The company’s facility is clean and organized, with separate areas for raw material storage, production, testing, and shipping. The company’s commitment to quality is evident in every aspect of their operations, from the selection of raw materials to the final shipment. The company’s testing data is a valuable resource for researchers, and they encourage its use in publications and presentations. The company’s website also includes a blog with articles on peptide research, quality control, and industry news. This helps to educate the community and promote best practices. The company’s mission is to provide researchers with the tools they need to make breakthroughs, and testing is a critical part of that mission. The company’s success is a testament to the importance of transparency and quality in the research peptide industry. The company’s future looks bright, with plans to expand their product line, improve their testing capabilities, and reach more researchers around the world. The company’s commitment to testing is unwavering, and they will continue to invest in new technologies and methods to ensure that their peptides meet the highest standards. The company’s data shows that their approach works, and they are proud to share it with the community. The company’s testing is not just a checkbox—it is a continuous process of improvement. The company’s team is dedicated to providing the best possible products, and they are always looking for ways to do better. The company’s testing data is a reflection of that dedication, and it is available to anyone who wants to see it. The company’s website is the best place to start, with detailed product pages and CoAs for every batch. The company’s support team is also available to answer any questions. The company’s testing is a key part of their value proposition, and it is one of the reasons why researchers trust them. The company’s reputation is built on data, not hype, and that is why they are a leader in the research peptide industry. The company’s testing data is a powerful tool for researchers, and it is available at their fingertips. The company’s commitment to quality is unmatched, and they will continue to set the standard for years to come. The company’s testing is the foundation of their business, and they will never compromise on it. The company’s data is their most valuable asset, and they are happy to share it. The company’s future is bright, and they are excited to see what researchers will discover with their products. The company’s testing is a promise, and they keep it. The company’s data is real